Skip to main content

Table 4 Patient characteristics of the MDS/low blast count AML cohort subjected to methylation analyses

From: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients

Number of patients

62

Age (years; median and range)

70.5 (20–83)

Sex

 

 Male

40

 Female

22

FAB subtype

 

 RA

17

 RARS

2

 RAEB

35

 RAEB-t

5

 CMML

3

IPSS risk category

 

 Low

5

 Intermediate I

17

 Intermediate II

30

 High

10

 Del(7q) or -7 (%)

11 (18)

  1. CMML chronic myelomonocytic leukemia, IPSS International Prognostic Scoring System, RA refractory anemia, RAEB refractory anemia with blast excess, RAEB-t refractory anemia with blast excess in transformation (i.e., acute myeloid leukemia according to the World Health Organization classification), RARS refractory anemia with ring sideroblasts